Nurix Therapeutics (NRIX) executive compensation, 2026 proxy

Arthur T. Sands, President, Chief Executive Officer and Director, was paid $6.4M in 2025, up 10% from $5.8M the year before. The CEO-to-median-employee pay ratio was 23:1, on median employee pay of $274,252.

Filed
March 27, 2026
Pay year
2025
Named executives
4
CEO total pay
$6.4M+10% vs prior year
CEO to median employee
23:1median $274,252
Prior say-on-pay support
81%of votes cast
CEO At-Risk Pay
89%Percentage of total target compensation
CEO Target Bonus
$510,000Non-equity incentive target
Say-on-Pay Support
81.4%Prior year advisory vote

How Sands was paid

$6.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary11%Option awards81%Non-equity incentive8%All other compensation0%

Named executive officers

ExecutiveTotal
Arthur T. SandsPresident, Chief Executive Officer and Director$6,374,138
Hans van HouteChief Financial Officer$2,296,503
Gwenn M. HansenChief Scientific Officer$2,498,124
Christine RingChief Legal Officer and Chief Compliance Officer$2,263,337

What changed and why

  • $6.4MChief executive officer total compensation increased to $6,374,138 in fiscal 2025 from $5,812,862 in fiscal 2024.
  • 81.4%Stockholders approved the executive compensation program with approximately 81.4% support at the prior annual meeting.
  • 89%Executive compensation is heavily weighted toward variable and at-risk pay, with 89% of target CEO compensation at-risk.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.